Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
Status:
Completed
Trial end date:
2019-01-23
Target enrollment:
Participant gender:
Summary
This study examines patients on chronic hemodialysis with non-valvular atrial fibrillation,
who have a CHA2DS2-VASc Score of ≥ 2 and therefore are candidates for or already receive a
vitamin K antagonist.
The first question is whether replacement of the vitamin K antagonist by rivaroxaban is able
to slow progression of vascular calcification. The second question is whether addition of
vitamin K2 to rivaroxaban can further slow down or even halt the progression of vascular
calcification.
Phase:
Phase 4
Details
Lead Sponsor:
Onze Lieve Vrouw Hospital
Treatments:
Rivaroxaban Vitamin K Vitamin K 2 Vitamin MK 7 Vitamins